A Phase IIa, Multi-Centre, Randomized, Double-Blind, Two-Part, Controlled, Repeated-Dose Study of AK106-001616 in Patients with Rheumatoid Arthritis.
Phase of Trial: Phase II
Latest Information Update: 27 Jul 2016
At a glance
- Drugs AK 106-001616 (Primary) ; Methotrexate (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Asahi Kasei
- 16 Nov 2011 Actual initiation date changed from 1 May 2009 to 24 Mar 2009 and official title amended as reported by European Clinical Trials Database.
- 08 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Dec 2009 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.